[12, 13, 14] Although this approach has mainly been used in cancer immunotherapy to activate cytotoxic T lymphocytes (CTLs) against tumor antigens, several immunogenic peptide therapeutics have been developed as well for autoimmune diseases including SLE, [15,16] rheumatoid arthritis, [17,18] type 1 diabetes, [19,20] and multiple sclerosis, [21] with varying success
The reduction of MYCN protein levels in MYCN-driven brain tumors is of major importance due to its central role as an oncogenic driver (71)
For randomised clinical trials, the Jadad scale ( To complement the Jadad score, the Cochrane Risk of Bias Tool (RoB 2) ( For observational studies (cohort and case-control), the NewcastleOttawa Scale (NOS) ( Risk of bias was interpreted as follows: i) Low risk: All criteria met or no more than one rated as unclear
Values are approximate and may vary depending on route of administration, formulation, species, and assay methodology
Luhby AL, Cooperman JM, Donnenfeld AM, Herrero JM, Teller DN, Wenig JB
Like the peptides themselves, however, the combinations of agents have not been well studied
